BG Medicine Aims to Raise $67M in IPO; Continues Transition from Services to Diagnostics Development

In an amended preliminary prospectus for its IPO filed this week, the company noted that it plans to apply more than half the funds raised by the offering to the development of its BGM Galectin-3, AMIPredict, and LipidDx protein biomarker products.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.